Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits

Patent metadata

Field	Value
Publication number	US-9328150-B2
Application number	US-201314048264-A
Country	US
Kind code	B2
Filing date	Oct 8, 2013
Priority date	Jan 11, 2005
Publication date	May 3, 2016
Grant date	May 3, 2016

Abstract

The inventive subject matter relates to a recombinant polypeptide construct comprising enterotoxigenic Escherichia coli fimbrial subunits. The recombinant polypeptide constructs comprise multiple subunits to the same or different ETEC fimbrial types. The constructs are useful for inclusion in immunogenic formulations for the inductin of immunity against entertoxigenic Escherichia coli . The inventive subject matter also relates to the use of the recombinant polypeptide constructs in induce anti-enterotoxigenic Escherichia coli.

First claim

What is claimed is:

1. A recombinant polypeptide construct comprising a whole or immunogenic fragment of an Escherichia coli fimbrial minor or major subunit connected to one or more major fimbrial subunits or immunogenic fragments, thereof, of the same fimbrial type, via a polypeptide linker, and wherein each of the one or more major fimbrial subunits contain a donor β strand and are also connected to each other via a polypeptide linker, wherein the C-terminal Escherichia coli fimbrial major subunit is connected, via a linker, to a C-terminal donor β strand derived from a major Escherichia coil fimbrial subunit that is homologous or heterologous to the immediately N-terminal major subunit and wherein said composition can comprise a histidine tag at the C-terminus.

2. The recombinant polypeptide construct of claim 1 , wherein fimbrial types are selected from fimbriae derived from Escherichia coli selected from the group consisting of class 5a, class 5b, class 5c, CS3 and CS6.

3. The recombinant polypeptide construct of claim 1 , wherein donor β strand contains 12 to 16 amino acids.

4. The recombinant polypeptide construct of claim 1 , wherein said N-terminus of said minor or major subunit contains an 18-22 amino acid signal peptide.

5. The recombinant polypeptide construct of claim 1 , wherein the amino acid sequence of said polypeptide linker is SEQ ID No. 5 or a tri-glycine.

6. The recombinant polypeptide construct of claim 1 , wherein one or more major subunits contain a deletion of the 14 to 18 N-terminal amino acids.

7. The recombinant polypeptide construct of claim 1 , wherein said construct is connected to one or more constructs, according to claim 1 , wherein each of the constructs contain fimbrial subunits derived from a different fimbrial type than any of the other constructs and wherein the recombinant polypeptide construct can contain a C-terminal histidine tag.

8. The recombinant polypeptide construct of claim 1 , wherein the C-terminal homologous or heterologous donor β strand is connected, via a polypeptide linker, to a bacterial toxin to form a chimeric molecule and wherein said bacterial toxin is noncovalently connected to a bacterial toxin multimeric composition.

9. The recombinant polypeptide construct of claim 1 , wherein said Escherichia coli fimbrial minor subunit is selected from the group consisting of CfaE, CsfD, CsuD, CooD, CsbD, CosD, CsdD, CotD and wherein said major subunit is selected from the group consisting of CfaB, CsfA, CsuA2, CooA, CsdA, CosA, CsbA, CotA, CstG, CstH, CssA, and CssB, or immunogenic fragments or derivatives, thereof.

10. The recombinant polypeptide of claim 7 , wherein said constructs are connected via one or more glycine residues.

11. The recombinant polypeptide construct of claim 7 , wherein said donor β strand contains 12 to 16 amino acids.

12. The recombinant polypeptide construct of claim 7 , wherein said N-terminus of said minor or major subunit contains an 18-22 amino acid signal peptide.

13. The recombinant polypeptide construct of claim 7 , wherein one or more major subunits contain a deletion of the N-terminal 14 to 18 amino acids.

14. The recombinant polypeptide construct of claim 7 , wherein said minor or major Escherichia coli fimbrial subunits are derived from ETEC strains selected from the group consisting of Class 5, CS3 and CS6.

15. The recombinant polypeptide construct of claim 7 , wherein said Escherichia coli fimbrial minor subunit is selected from the group consisting of CfaE, CsfD, CsuD, CooD, CsbD, CosD, CsdD, CotD and wherein said major subunit is selected from the group consisting of CfaB, CsfA, CsuA1, CsuA2, CooA, CsdA, CosA, CsbA, CotA, CstG, CstH, CssA, and CssB, or immunogenic fragments, or derivatives thereof.

16. The recombinant polypeptide construct of claim 7 , wherein the amino acid sequence of said linker is SEQ ID No. 5 or a triglyicine.

17. The recombinant polypeptide construct of claim 8 , wherein said bacterial toxin is cholera toxin and wherein said multimeric bacterial composition is LTB 5 , wherein said construct has the amino acid sequence selected from the group consisting of SEQ ID No. 37, 41, and 43 and wherein said bacterial toxin multimeric composition has the amino acid sequence of SEQ ID No. 39.

18. The recombinant polypeptide of claim 9 , wherein said amino acid sequence of said Escherichia coli fimbrial minor subunit is selected from the group consisting of SEQ ID Nos. 45, 46, 51, 52, 57, 58, 65, 71, 75, 79, 83, 88, 90, 93, 95, and 97, or derivatives thereof, and wherein said amino acid sequence of said Escherichia coli fimbrial major subunit is selected from the group consisting of SEQ ID Nos. 2, 4, 48, 49, 54, 55, 60, 61, 63, 67, 69, 73, 77, 81, 85, 87, 89, 91, 92, 94, 96, 98, 99, 101, 135, and 137, or derivatives thereof.

19. The recombinant polypeptide of claim 9 , wherein said minor subunit is encoded by the nucleotide sequence selected from the group consisting of SEQ ID No. 44, 50, 56, 64, 70, 74, 78, 82, 115, 117, 119, 122, 124, 127, 129, and 133, or derivatives, thereof, and wherein said major subunit is encoded by the nucleotide sequence selected from the group consisting of SEQ ID No. 1, 3, 47, 53, 59, 62, 66, 68, 72, 76, 80, 84, 86, 116, 118, 120, 121, 123, 125, 126, 128, 130, 131, 132, 134, and 136, or derivatives thereof.

20. The recombinant polypeptide construct of claim 10 , wherein said construct is encoded by the nucleotide sequence selected from the group consisting of SEQ ID No. 36, 40 and 42 and wherein said bacterial toxin multimeric composition has the amino acid sequence of SEQ ID No. 38.

21. The recombinant polypeptide of claim 15 , wherein said amino acid sequence of said Escherichia coli fimbrial minor subunit is selected from the group consisting of SEQ ID Nos. 45, 46, 51, 52, 57, 58, 65, 71, 75, 79, 83, 88, 90, 93, 95, and 97, or derivatives thereof, and wherein said amino acid sequence of said Escherichia coli fimbrial major subunit is selected from the group consisting of SEQ ID Nos. 2, 4, 48, 49, 54, 55, 60, 61, 63, 67, 69, 73, 77, 81, 85, 87, 89, 91, 92, 94, 96, 98, 99, 101, 135, and 137, or derivatives thereof.

22. The recombinant polypeptide of claim 15 , wherein said minor subunit is encoded by the nucleic acid sequence selected from the group consisting of SEQ ID No. 44, 50, 56, 64, 70, 74, 78, 82, 115, 117, 119, 122, 124, 127, 129, and 133, or derivatives thereof, and wherein said major subunit is encoded by the nucleic acid sequence selected from the group consisting of SEQ ID No. 1, 3, 47, 53, 59, 62, 66, 68, 72, 76, 80, 84, 86, 116, 118, 120, 121, 123, 125, 126, 128, 130, 131, 132, 134, and 136, or derivatives thereof.

Assignees

• Savarino Stephen
• Us Navy

Inventors

• Savarino Stephen

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61K39/0258

  Escherichia · CPC title

• A61K2039/543

  intranasal · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K2039/70

  Multivalent vaccine · CPC title